This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of intervention
Diagnosis and treatment.
Economic study type
Cost-utility analysis.
Study population
As this was a modelling study, the target population comprised a hypothetical cohort of individuals aged between 30 and 64 years of whom 85% were men. The cohort included individuals at moderate to high risk of OSAS (OSAS indicative symptoms were excessive daytime somnolence, persistent snoring and witnessed apnoeas during sleep).
Setting
The interventions appear to have been provided in an inpatient setting (sleep laboratory) and in the community (patients' residence). The economic study was carried out in the USA.
Dates to which data relate
The effectiveness data used to populate the model came from studies published between 1984 and 2003. The resource use data were derived from studies published between 1990 and 2003 and were augmented by authors' assumptions. The cost data were derived from official sources (Medicare Fee Schedule reimbursement rates) and referred to the year 2004. All costs were reported for the price year 2004.
Methods used to judge relevance and validity, and for extracting data
The process used to identify the data was not reported. Although the authors stated that the data referred to similar study populations to the hypothetical cohort of the study, explicit inclusion criteria were not specified. The method used to select the estimates was neither reported nor discussed. It was reported that when published literature suggested more than one probability, a mean value weighted by sample size was used.
Measure of benefits used in the economic analysis
The measure of benefit used was the quality-adjusted life-years (QALYs). The utility values were derived from published studies, while life expectancy estimates for the health states over the 5-year horizon were calculated from published data. Utility values were discounted at an annual rate of 3%.
Direct costs
The study reported direct costs to the third-party payer. These were full-and split-night PSG, polysomnographic CPAP titration and autotitration, UHPSM, office visits, and the costs of CPAP rental and accessories (1, 2, and 3 to 5 years). Cost estimates were based on procedure reimbursement rates, derived from the Medicare Fee Schedule. The resources used appear to have been mainly derived from published studies. The costs were discounted at an annual rate of 3% and were reported for the price year 2004. Although assumptions about resource use were reported, the unit costs and the resource quantities were not reported separately.
The home study and the split-night polysomnography (PSG) strategies were more cost-effective in comparison with full-night PSG.
CRD COMMENTARY -Selection of comparators
All three diagnostic strategies appear to have been commonly used approaches, with full-night PSG representing the most conventional strategy in the authors' settings. However, alternative treatment procedures to CPAP titration (i.e. oral appliances, surgical procedures) or alternative combination strategies (i.e. full-night PSG followed by home CPAP autotitration) were not accounted for in the model. These factors mean that the study was only a partial analysis. You should decide if these strategies represent widely used technologies in your own setting.
Validity of estimate of measure of effectiveness
The parameters were derived from published research, but no systematic search for data was reported. In certain cases, a mean value weighted according to sample size was used in the model; however, it was not clear for which parameters the calculations were performed. The authors did not report any search methods or inclusion criteria, nor did they provide any justification for their selection of the estimates. It is not possible to judge the quality of the evidence used to derive input model parameters, given the limited information reported.
Validity of estimate of measure of benefit
The estimation of health benefits (QALYs) was modelled using a Markov model. The utilities were taken from published studies and no details of the valuation method were reported.
Validity of estimate of costs
The analysis of the costs was performed from the perspective of the third-party payer. Direct health care costs due to complications of untreated OSAS were omitted from the analysis, but their omission is likely to have affected the costeffectiveness results. Medicare procedure reimbursement rates were used as a proxy for costs, which was acceptable given the perspective adopted. However, this may have implications for the generalisability of the study beyond the study setting. You should consider whether U.S. Medicare reimbursement costs are likely to be similar to the costs in your own setting. The cost estimates were assigned prior distributions to characterise their uncertainty. The authors evaluated uncertainty in the cost data jointly with the effectiveness data in order to produce cost-effectiveness planes. The costs were appropriately discounted and the price year was reported, thus facilitating future reflation exercises.
Other issues
The authors briefly discussed the results of previous studies and acknowledged that methodological differences in study designs do not enable detailed direct comparisons. The authors acknowledged variation in different patient populations (e.g. asymptomatic or low-risk patients, paediatric or geriatric populations), but did not evaluate the impact of this on the economic results through a sensitivity analysis. The authors do not appear to have presented their results selectively and their conclusions reflected the scope of their analysis.
